TAKANASHI KEN

SEC Form 4 insider trading activity

TAKANASHI KEN has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.

On the most recent filing, TAKANASHI KEN is listed as Director at Wave Life Sciences, Inc. Inside the rolling window, TAKANASHI KEN reported no open-market purchases and 1 open-market sale totaling $23K in WVE.

Companies traded

Other insiders at WVE

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$23K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
WVE
TAKANASHI KEN
Sale$23KAug 14SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has TAKANASHI KEN made?

TAKANASHI KEN has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.

Which companies does TAKANASHI KEN trade?

TAKANASHI KEN has filed SEC Form 4 disclosures for 1 company, including WVE.

When was TAKANASHI KEN's most recent SEC Form 4 filing?

TAKANASHI KEN's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.

What is TAKANASHI KEN's total buy and sell value in the current window?

Inside the rolling retention window, TAKANASHI KEN bought $0 and sold $23K based on SEC Form 4 filings.

What was TAKANASHI KEN's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 3,864 WVE shares on 2026-08-11, worth $23K, per SEC Form 4 filings.